The summer 2024 COVID-19 wave is a good reminder that it’s important to get vaccinated with the updated shot.
Academic rigor, journalistic flair
Articles on RSV
Displaying 1 - 20 of 37 articles
RSV is most common in kids under 5. Research suggests it could cause asthma, but we need to know more.
The vaccine protects newborn babies through antibodies that cross the placenta.
You wake with a sore throat and realise you are sick. Is this going to be a two-day or a two-week illness? Here’s how to tell the difference between these common infections.
At the moment, a child’s access to certain shots can differ depending on whether they live in Queensland or Tasmania.
The RSV shot children in WA will get is a monoclonal antibody. Here’s what that means.
On the fourth anniversary of New Zealand’s first COVID case it’s clear this is not a normal pandemic. Despite fatigue and indifference, New Zealand must heed the evidence and improve its response.
The TGA has just approved a vaccine against RSV for Australians over 60. Here’s where protection is up to for the youngest children, who are also at risk from the virus.
The current triple epidemic of respiratory viruses is affecting all age groups, prompting comparisons with the pre-COVID-19 era.
There are a number of pathogens which are reported to be causing the outbreak of respiratory illness in China.
Newly approved and updated vaccines are the best tools available to combat COVID-19, the flu and RSV, as infections and hospitalizations tick upward and cold and flu season gets underway.
Nearly 100,000 US children under age 5 are hospitalized each year for an RSV infection.
Even otherwise healthy children can end up in hospital with this winter respiratory virus.
The newly approved RSV vaccine could be rolled out by fall 2023, in time for the typical winter surge in RSV infections.
The first vaccine against respiratory syncytial virus is 83% effective.
Some of the prescription medications you’re taking may not mix with over-the-counter drugs.
Similar to the patterns seen with COVID-19, flu and RSV, HMPV is making a comeback after years of being repressed by people wearing masks and social distancing.
Here’s why it’s taken so long to develop a vaccine for respiratory syncytial virus and what we can expect next.
A combination of high demand and poor stock planning may explain current problems.
Evidence-based tools for dialectical behaviour therapy can help us manage family stressors during the virulent respiratory virus season.
Top contributors
-
Associate Professor of Epidemiology, University of San Francisco
-
Associate Professor of Pediatric Infectious Diseases, Baylor College of Medicine
-
Professor of Infectious Diseases, Monash University
-
Paediatric Respiratory Physician, and Honorary Fellow Manager, Murdoch Children's Research Institute
-
Senior Research Officer, Murdoch Children's Research Institute
-
Paediatrician, Infectious Diseases Physician and Clinical Microbiologist, Telethon Kids Institute, The University of Western Australia
-
General Practitioner, PhD Candidate, Bond University
-
Associate Professor of Paediatric Infectious Diseases, University of Southampton
-
Infectious Diseases and Microbiology Clinical Research Training Fellow, University of Southampton
-
Senior Clinical Lecturer, Paediatric Infectious Diseases and Immunology, Imperial College London
-
Clinical Professor of Pharmacy Practice, University of Connecticut
-
Section head and Medical Director of Pediatric Emergency, Winnipeg Children's Hospital, Assistant Professor of Pediatrics and Child Health, University of Manitoba
-
Professor of Paediatrics and vaccinologist, Royal Childrens Hospital, University of Melbourne and Murdoch Childrens Research Institute (MCRI); Associate Dean International, University of Melbourne, Murdoch Children's Research Institute
-
Infectious diseases epidemiologist, The Kids Research Institute Australia
-
Senior Lecturer, Department of Child and Youth Health, University of Auckland, Waipapa Taumata Rau
